LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Purchased by Russell Investments Group Ltd.

Russell Investments Group Ltd. raised its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 6.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 288,212 shares of the medical instruments supplier's stock after acquiring an additional 18,223 shares during the quarter. Russell Investments Group Ltd. owned approximately 1.29% of LeMaitre Vascular worth $16,359,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Envestnet Asset Management Inc. raised its stake in LeMaitre Vascular by 24.8% during the 3rd quarter. Envestnet Asset Management Inc. now owns 195,983 shares of the medical instruments supplier's stock worth $10,677,000 after acquiring an additional 38,958 shares during the period. Vanguard Group Inc. raised its position in shares of LeMaitre Vascular by 2.3% during the 3rd quarter. Vanguard Group Inc. now owns 1,510,567 shares of the medical instruments supplier's stock valued at $82,296,000 after purchasing an additional 33,500 shares during the period. Conestoga Capital Advisors LLC lifted its stake in shares of LeMaitre Vascular by 0.5% during the 4th quarter. Conestoga Capital Advisors LLC now owns 1,927,971 shares of the medical instruments supplier's stock valued at $109,432,000 after buying an additional 10,390 shares in the last quarter. Johnson Investment Counsel Inc. boosted its holdings in LeMaitre Vascular by 52.6% in the 3rd quarter. Johnson Investment Counsel Inc. now owns 32,745 shares of the medical instruments supplier's stock worth $1,784,000 after buying an additional 11,280 shares during the period. Finally, Dark Forest Capital Management LP increased its stake in LeMaitre Vascular by 152.9% in the 3rd quarter. Dark Forest Capital Management LP now owns 13,857 shares of the medical instruments supplier's stock worth $755,000 after buying an additional 8,378 shares in the last quarter. Institutional investors own 84.64% of the company's stock.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, Director John A. Roush sold 7,500 shares of the stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $69.00, for a total value of $517,500.00. Following the sale, the director now owns 2,278 shares in the company, valued at $157,182. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, Director Lawrence J. Jasinski sold 5,110 shares of the company's stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $67.50, for a total value of $344,925.00. Following the completion of the sale, the director now directly owns 5,309 shares of the company's stock, valued at $358,357.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director John A. Roush sold 7,500 shares of the stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $69.00, for a total transaction of $517,500.00. Following the transaction, the director now owns 2,278 shares in the company, valued at $157,182. The disclosure for this sale can be found here. Insiders have sold 114,036 shares of company stock worth $7,873,749 over the last quarter. Insiders own 10.79% of the company's stock.

Analyst Ratings Changes

LMAT has been the topic of several research analyst reports. JMP Securities boosted their price objective on LeMaitre Vascular from $72.00 to $77.00 and gave the company a "market outperform" rating in a research report on Friday. Barrington Research increased their price objective on shares of LeMaitre Vascular from $69.00 to $79.00 and gave the company an "outperform" rating in a report on Friday. KeyCorp assumed coverage on shares of LeMaitre Vascular in a report on Tuesday, February 6th. They issued a "sector weight" rating on the stock. Stifel Nicolaus raised shares of LeMaitre Vascular from a "hold" rating to a "buy" rating and raised their target price for the company from $59.00 to $75.00 in a research note on Friday, April 26th. Finally, StockNews.com upgraded shares of LeMaitre Vascular from a "hold" rating to a "buy" rating in a research note on Friday. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $73.83.

LeMaitre Vascular Stock Up 11.2 %

LeMaitre Vascular stock traded up $7.45 during mid-day trading on Friday, reaching $74.22. 329,984 shares of the company's stock traded hands, compared to its average volume of 110,751. LeMaitre Vascular, Inc. has a 12-month low of $44.27 and a 12-month high of $74.64. The stock has a 50 day moving average of $65.93 and a two-hundred day moving average of $58.78. The company has a market cap of $1.67 billion, a price-to-earnings ratio of 49.15, a PEG ratio of 2.88 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share for the quarter, topping analysts' consensus estimates of $0.39 by $0.05. LeMaitre Vascular had a net margin of 16.99% and a return on equity of 11.75%. The firm had revenue of $53.48 million for the quarter, compared to the consensus estimate of $51.50 million. During the same period in the previous year, the firm posted $0.27 EPS. The business's quarterly revenue was up 13.6% on a year-over-year basis. As a group, sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.66 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 30th. Stockholders of record on Thursday, May 16th will be given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.86%. The ex-dividend date of this dividend is Wednesday, May 15th. LeMaitre Vascular's dividend payout ratio is currently 42.38%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.